Journal article icon

Journal article

Initiation of adjuvant chemotherapy and trastuzumab for human epidermal growth receptor 2-positive early invasive breast cancer in a population-based cohort study of older women in England

Abstract:

Background Clinical guidance on recommended treatment for older patients with breast cancer is often ambiguous, particularly in the context of comorbidities and poor functional status. Older patients, aged 70 years and over, account for a substantial proportion of women with breast cancer yet are underrepresented in randomized controlled trials. This paper investigates the initiation of adjuvant chemotherapy and trastuzumab in older patients in routine care.

Materials and methods Women, aged 50 years and over, newly diagnosed with human epidermal growth receptor 2 (HER2)-positive early invasive breast cancer from January 2014 to December 2017 were identified from the England Cancer Registry. Chemotherapy and trastuzumab use was obtained from the Systemic Anti-Cancer Therapy (SACT) dataset. Patient and tumor characteristics influential in treatment decision-making were included in multilevel mixed-effects logistic regression models.

Results 10% of women had HER2-positive tumors. Initiation of adjuvant chemotherapy and trastuzumab decreased with age from ≥70% among women aged 50–64 years to <15% among women aged 80+ years. Initiation varied additionally by tumor characteristics and number of comorbidities. Age remained a factor in treatment decisions despite favorable other factors, with lower use among women aged 70+ years. There was also marked variation across geographical regions.

Conclusions In women with operable HER2-positive early invasive breast cancer, adjuvant chemotherapy plus trastuzumab was started less frequently as age increased, regardless of tumor characteristics or comorbidity burden. There was substantial variation in the proportion of women who started these treatments across the country.

Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1016/j.jgo.2020.01.005

Authors

More by this author
Division:
MSD
Role:
Author
More by this author
Division:
MSD
Department:
Nuffield Department of Population Health
Sub department:
Clinical Trial Service Unit
Role:
Author
ORCID:
0000-0001-8787-4904
More by this author
Division:
MSD
Role:
Author
More by this author
Division:
MSD
Role:
Author


Publisher:
Elsevier
Journal:
Journal of Geriatric Oncology More from this journal
Volume:
11
Issue:
5
Pages:
836-842
Publication date:
2020-01-29
Acceptance date:
2020-01-06
DOI:
ISSN:
1879-4068


Language:
English
Keywords:
Pubs id:
1084160
Local pid:
pubs:1084160
Deposit date:
2020-01-30
ARK identifier:

Terms of use


Views and Downloads

Views and downloads will return soon






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP